Prothena Reports Strong Q1 Net Income Driven by $50M Coramitug Milestone, Advances Key Clinical Programs
PRTA has more than doubled off its 52-week low of $4.32.
Summary
Prothena reported a net income of $32.7 million in Q1 2026, a significant reversal from a prior-year loss, fueled by a $50 million milestone payment for its Coramitug program and positive operating cash flow, alongside continued advancement of its clinical pipeline.
Key Events · Earnings and Guidance · PRTA
-
Achieved Q1 Net Income of $32.7 Million
The company reported a net income of $32.7 million for the three months ended March 31, 2026, a substantial improvement from a net loss of $60.2 million in the same period last year.
-
Received $50 Million Coramitug Milestone Payment
Revenue was significantly boosted by a $50 million development milestone payment from Novo Nordisk related to the advancement of coramitug in its Phase 3 CLEOPATTRA clinical trial.
-
Generated Positive Operating Cash Flow
Net cash provided by operating activities was $28.9 million for Q1 2026, a strong turnaround from $53.4 million used in operating activities in Q1 2025.
-
Advanced Multiple Clinical Programs
Key pipeline updates include the initiation of Phase 3 trials for Prasinezumab (Parkinson's) and Coramitug (ATTR amyloidosis), and Fast Track designations for Coramitug and BMS-986446 (Alzheimer's).
Analysis · PRTA · Life Sciences
Prothena has reported a significant financial turnaround in Q1 2026, moving from a substantial net loss in the prior year to a net income of $32.7 million. This positive shift was primarily driven by a $50 million development milestone payment from Novo Nordisk for the continued advancement of coramitug in its Phase 3 clinical trial. The company also demonstrated a strong improvement in operational efficiency, generating $28.9 million in cash from operations compared to a significant cash burn in the prior year. This financial strength, coupled with ongoing progress in multiple late-stage clinical programs and a continued share repurchase program, signals robust operational execution and a positive outlook for investors.
At the time of this filing, PRTA was trading at $10.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $566.3M. The 52-week trading range was $4.32 to $11.69. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.